Sorry, you need to enable JavaScript to visit this website.

Competitive Grants Program

Pfizer supports the global healthcare community’s independent initiatives (e.g., research, quality improvement or education) to improve patient outcomes in areas of unmet medical need that are aligned with Pfizer’s medical and/or scientific strategies.

Pfizer’s competitive grant program involves a publicly posted Request for Proposal (RFP) that provides detail regarding a specific area of interest and sets timelines for review and approval. Organizations are invited to submit an application addressing the specific gaps in research, practice or care as outlined in the specific RFP. The grant requester (and ultimately the grantee) is responsible for the design, implementation, sponsorship, and conduct of the independent initiative supported by the grant, including compliance with any regulatory requirements.

Sign up to receive all grant announcements, including Request for Proposal (RFP) postings.

Sign Up for Alerts Details
  • Title
    Grant Type
    Focus Area
    Country
    Application Due Date
    Biochemical and Molecular Characterization of Marstacimab and TFPI Pathways
    Release Date:
    Review Process: Pfizer Internal
    Research Rare Disease Brazil, China, Germany, Italy, Japan, Korea, Netherlands, Saudi Arabia, Spain, Turkey, USA, United Kingdom
    Optimizing RSV diagnosis by improving RSV detection in patients admitted to ED/hospitalized due to respiratory symptoms
    Release Date:
    Review Process: Pfizer Internal
    Quality Improvement Vaccines Austria, Belgium, Bulgaria, Czech Republic, Finland, Greece, Ireland, Israel, Luxembourg, Netherlands, Norway, Poland, Portugal, Romania, Slovakia (Slovak Republic), Sweden, Switzerland
    Investigating the Benefit of Early Treatment with Ritlecitinib in Alopecia Areata: A Real-World Evidence Approach
    Release Date:
    Review Process: Pfizer Internal
    Research Inflammation & Immunology USA
    Guideline Concordant Care and Emerging Data for Patients with MIBC through la/mUC
    Release Date:
    Partner: Astellas
    Review Process: Pfizer Internal
    Education Oncology USA
    Advancing Genomic Competence and Patient Centered Care in Metastatic Breast Cancer
    Release Date:
    Review Process: Pfizer Internal
    Education Oncology Canada, China, France, Germany, India, Italy, Japan, Spain, United Kingdom
    AI-Enabled Models for Timely COVID-19 Treatment with Nirmatrelvir/Ritonavir: Eligibility & Drug–Drug Interaction Management
    Release Date:
    Review Process: Pfizer Internal
    Research Internal Medicine Australia, Canada, Germany, Greece, Japan, Korea, Taiwan
    Clinical Data Updates on Long Term Outcomes and Practical Therapy Management Strategies in First-line ALK-posit
    Release Date:
    Review Process: Pfizer Internal
    Education Oncology United States Minor Outlying I
    OPTIMA-HEMA Project: Optimizing the Management and Application of Novel Immunotherapies in Hematologic Malignancies
    Release Date:
    Review Process: Pfizer Internal
    Quality Improvement Oncology China
    Advancing Adult Immunization Strategies:A Focus on the Impact of Respiratory Syncytial Virus(RSV) and Cardiorespiratory Outcome
    Release Date:
    Review Process: Pfizer Internal
    Education Vaccines USA
    Implementing Shared Decision Making in Hemophilia Patient Care
    Release Date:
    Review Process: Pfizer Internal
    Quality Improvement Rare Disease USA
  • Title
    Grant Type
    Focus Area
    Country
    Application Due Date
    Emerging Mechanisms of Action in the Treatment of Moderate-to-Severe Atopic Dermatitis
    Release Date:
    Review Process: Pfizer Internal
    Education Inflammation & Immunology All
    Pharmacist Education in Biosimilars (Western Europe, Canada, Japan)
    Release Date:
    Review Process: Pfizer Internal
    Education Oncology All
    Biosimilars in Hematologic Malignancies & Supportive Care
    Release Date:
    Review Process: Pfizer Internal
    Education Oncology All
    The Burden and Origins of Co-Infections in COVID-19 Pneumonia (Europe)
    Release Date:
    Review Process: Pfizer Internal
    Education Hospital All
    Needs Assessment – Early Therapy Management with CDK 4/6 Inhibitors in Metastatic Breast Cancer
    Release Date:
    Review Process: Pfizer Internal
    Education Oncology USA
    Advances in Atopic Dermatitis for Advanced Practitioners
    Release Date:
    Review Process: Pfizer Internal
    Education Inflammation & Immunology USA
    2020 RD US- Next Generation PET Imaging for ATTR-CM
    Release Date:
    Partner: GE Healthcare
    Review Process: Expert Review Panel
    Research Rare Disease USA
    Cardiac Transthyretin Amyloid (ATTR) Fellowship Competitive Grant Program
    Release Date:
    Partner: International Society of Amyloidosis
    Review Process: Expert Review Panel
    Fellowship Rare Disease All
    Management of Moderate-to-Severe Atopic Dermatitis for Dermatologists and Allergists
    Release Date:
    Review Process: Pfizer Internal
    Education Inflammation & Immunology USA
    Pfizer and Mayo Clinic/Global Bridges–Providing Access to Learning Resources for Tobacco Dependence Treatment
    Release Date:
    Partner: Mayo Clinic/Global Bridges
    Review Process: Expert Review Panel
    Education Internal Medicine China, Malaysia, Taiwan, Thailand
    2021 Rheumatology Competitive Grant Program
    Release Date:
    Review Process: Expert Review Panel
    Research Inflammation & Immunology USA
    4th Quality Improvement initiatives optimizing AF and VTE management in Canada
    Release Date:
    Partner: Bristol-Myers Squibb
    Review Process: Pfizer Internal
    Quality Improvement Internal Medicine Canada